IFNG and Miyoshi myopathy: NK-92-based platforms expressing anti-BCMA CARs (including constructs that co-express pro-apoptotic payloads such as soluble TRAIL) showed enhanced killing of MM cell lines and primary samples, increased secretion of IFN-γ and granzyme B, and significant antitumor efficacy in xenograft models [25,128].